BlackRock Group’s Lifecore Biomedical LFCR Stock Holding History

BlackRock Group’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$139K	Buy	10,112 +1,090	+12%	+$15.1K	﹤0.01%	2761
2016 Q3	$121K	Buy	9,022 +2,772	+44%	+$33.6K	﹤0.01%	2780
2016 Q2	$68K	Hold	6,250	–	–	﹤0.01%	2863
2016 Q1	$66K	Sell	6,250 -15,622	-71%	-$172K	﹤0.01%	2863
2015 Q4	$259K	Hold	21,872	–	–	﹤0.01%	2441
2015 Q3	$255K	Buy	21,872 +2,385	+12%	+$31.6K	﹤0.01%	2451
2015 Q2	$281K	Hold	19,487	–	–	﹤0.01%	2471
2015 Q1	$272K	Sell	19,487 -5,849	-23%	-$80.8K	﹤0.01%	2390
2014 Q4	$350K	Sell	25,336 -2,820	-10%	-$36.4K	﹤0.01%	2347
2014 Q3	$345K	Buy	+28,156	New	+$351K	﹤0.01%	2297
2013 Q4	–	Sell	-242	Closed	-$3K	–	2734
2013 Q3	$3K	Buy	+242	New	+$3.38K	﹤0.01%	2884

Other funds holding LFCR

NIMC

NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

TAM

THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Group's LFCR Position: Q4 2016 in Review

BlackRock Group increased its Lifecore Biomedical (LFCR) stake by 12% in Q4 2016, buying an estimated $15.1K and bringing the position to 10,112 shares worth $139K. The position accounts for ﹤0.01% of the portfolio, ranked #2761.

BlackRock Group first reported a position in LFCR in Q3 2013 and has held it in 11 quarters since. The position peaked at $350K in Q4 2014. 93 funds tracked by Wall St. Rank hold LFCR as of Q4 2016.

BlackRock Group held 10,112 shares of Lifecore Biomedical worth $139K as of Q4 2016.
BlackRock Group bought 1,090 Lifecore Biomedical shares in Q4 2016, an estimated $15.1K.
Lifecore Biomedical made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2761 holding.
BlackRock Group first reported a position in Lifecore Biomedical in Q3 2013 and has held it in 11 quarters since.
BlackRock Group's Lifecore Biomedical position peaked at $350K in Q4 2014.
93 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.